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Running title: Systems analysis of cetuximab responses
Novelty and Impact: A large fraction of patients with metastatic colorectal cancer do 
not respond to anti-EGFR therapy despite KRAS wild type tumours. Statistical 
analysis of RPPA data of colorectal cancer KRAS, BRAF, NRAS and PI3KCA wild 
type PDX models revealed a 14 - 20 (phospho)protein signature that was predicting 
responses to cetuximab. Our findings furthermore emphasise GSK-3β to be 
potentially targetable for a co-treatment with cetuximab.
Keywords: anti-EGFR, metastatic colorectal cancer, molecular subtyping, reverse-
phase protein array, deterministic modelling, apoptosis, proliferation
Abbreviations: 5-FU, fluorouracil; ANOVA, analysis of variance; CMS, consensus 
molecular subtypes; CRC, colorectal cancer; CRIS, CRC intrinsic subtype; EGF, 
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selection operator; NMF, non-negative matrix factorization; P, p-value; PAM, 
Prediction Analysis for Microarrays; PDX, patient-derived mouse xenograft; RPPA, 
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Antibodies targeting the human epidermal growth factor receptor (EGFR) are used 
for the treatment of RAS wild-type metastatic colorectal cancer. A significant 
proportion of patients remains unresponsive to this therapy. Here, we performed a 
reverse phase protein array-based (phospho)protein analysis of 63 ‘quadruple-
negative’ (KRAS, NRAS, BRAF and PIK3CA wild-type) metastatic CRC tumours. 
Responses of tumours to anti-EGFR therapy with cetuximab were recorded in 
patient-derived xenograft (PDX) models. Unsupervised hierarchical clustering of pre-
treatment tumour tissue identified three clusters, of which cluster C3 was exclusively 
composed of responders. Clusters C1 and C2 showed mixed responses. None of the 
three protein clusters showed a significant correlation with transcriptome-based 
subtypes. Analysis of protein signatures across all PDXs identified 14 markers that 
discriminated cetuximab-sensitive and -resistant tumours: PDK1 (S241), Caspase-8, 
Shc (Y317), Stat3 (Y705), p27, GSK-3β (S9), HER3, PKC- (S657), EGFR (Y1068), 
Akt (S473), S6 Ribosomal Protein (S240/244), HER3 (Y1289), NF-B-p65 (S536) 
and Gab-1 (Y627). Least absolute shrinkage and selection operator and binominal 
logistic regression analysis delivered refined protein signatures for predicting 
response to cetuximab. (Phospo-)protein analysis of matched pre- and post-treated 
models furthermore showed significant reduction of Gab-1 (Y627) and GSK-3β (S9) 
exclusively in responding models, suggesting novel targets for treatment.
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Colorectal cancer (CRC) is the third and second most commonly 
diagnosed cancer in males and females, and the second most common 
cause of cancer-related deaths in the developed world. In the advanced 
setting, CRC is routinely treated with fluorouracil (5-FU)-based 
chemotherapy. 30% of CRC patients present in the metastatic setting1 
where response rates to palliative 5-FU/oxaliplatin- or 5-FU/irinotecan-
based chemotherapy range between 40-50%. Median overall survival 
remains poor at around 16-19 months2. Identifying the importance of 
epidermal growth factor (EGF) signalling for the survival of CRC cells 
resulted in the development of targeted therapies that neutralize the 
oncogenic activity of EGF receptors (EGFR). Anti-EGFR therapies have 
significantly improved survival in metastatic CRC patients3. Guidelines 
recommend to test for KRAS, NRAS and BRAF mutations as well as 
microsatellite instability status in CRC patients being considered for anti-
EGFR therapy4, 5 on the bases of the ineffectiveness of anti-EGFR therapy 
is not effective in patients with activating KRAS, BRAF, and NRAS 
mutations6, and favourable responses to immune check point inhibitors in 
microsatellite instability-high patients4. While PI3KCA mutational analysis 
is not recommended yet4, PIK3CA exon 20 mutations were linked with a 
worse outcome compared with wild-type status in patients with metastatic 
colorectal cancer 7. Nevertheless, between 50–60% of patients will not 
benefit from anti-EGFR treatment even when these are KRAS, BRAF, 
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NRAS and PI3KCA wild type (quadruple negative) have a ‘quadruple 
negative’ status7. 
Mutations and copy number alterations in genes encoding for other 
survival signaling proteins have been shown to contribute to anti-EGFR 
resistance. For example, HER2-amplification, IGF2 overexpression or 
increased MET activity resulted in reduced responses to anti-EGFR 
therapy, as demonstrated in patient-derived xenograft (PDX) models of 
metastatic CRC and in patients8, 9. Analysis of the genomic and 
transcriptomic landscape of anti-EGFR resistance in PDX models and 
patients furthermore identified mutations in EGFR, FGFR1, PDGFRA, and 
MAP2K1 or loss of NF1 to contribute to anti-EGF resistance9, 10.
While identification of patient-specific genome alterations provides a 
personalised diagnosis that provides insights into anti-EGFR therapy 
responses and may open opportunities for personalised therapies, 
interpretation of often multiple genomic alterations found in most patients 
is not always straightforward. Other efforts to identify responders and non-
responders to anti-EGFR therapy have therefore focussed on the power of 
unsupervised molecular subtyping of tumours. An international meta-
analysis and bioinformatics effort led to the identification of four distinct 
subtypes in CRC, termed ‘Consensus Molecular Subtypes’ (CMS1-
CMS4)11. A recent study demonstrated that CMS2 patients benefitted 
more from anti-EGFR therapy than patients treated with anti-angiogenic 
therapy, while the opposite was the case in CMS1 patients12. However 
predictions of anti-EGFR therapy responses in CMS3 and CMS4 patients 
were not possible, and significant variability in overall and progression free 
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survival are still seen across all four CMS subtypes. Because stroma-
derived mRNAs in whole tumour transcriptomes may obscure 
transcriptional features displayed by cancer cells, other efforts leveraged 
the power of patient-derived mouse xenograft (PDX) models in which 
human stroma is replaced by mouse stroma to obtain five CRC ‘intrinsic’ 
(CRIS) molecular subtypes, termed CRIS-A to E13. CRIS-C was identified 
as a subtype associated with EGFR signalling and increased sensitivity to 
anti-EGFR therapy. However responses to anti-EGFR therapy strongly 
varied among the other four CRIS subtypes 13.
EGFR activation results in the activation of several downstream signalling 
pathways, including the PI3K/AKT and MAPK pathways14. The activation 
status of these key signalling pathways influences a variety of biological 
processes such as proliferation, apoptosis, cell migration, bioenergetics, 
immune responses, and angiogenesis. A different approach to investigate 
responses to anti-EGFR therapy is to determine the activation status of 
key signalling branches activated by EGFR receptors and their 
downstream effectors, supported by statistical or deterministic modelling15. 
Because processes such as proliferation and apoptosis are controlled by 
complex networks that show significant signalling redundancies, 
deterministic systems models have been developed to estimate more 
precisely proliferative capacity or apoptosis sensitivity of tumours. One 
such tool developed by our group is the systems model, DR_MOMP, 
which calculates the apoptosis sensitivity of tumours based on a 
quantitative analysis of BCL-2 family proteins and their interactions16, 17. 
To identify novel prognostic markers of anti-EGFR therapy, we here 
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comprehensively profiled 83 signalling proteins and (phospho)proteins 
related to EGFR and key cancer signalling pathways in a cohort of 63 
‘quadruple negative’ (KRAS, BRAF, NRAS and PI3KCA wild type) PDX 
models isolated from liver biopsies that were derived from metastatic CRC 
patients9, 18. We performed both statistical and systems modelling 
analyses to identify novel protein signatures of anti-EGFR responsiveness.
Methods
CRC PDX in vivo model 
108 PDX models derived from colorectal cancer liver metastasis originally 
at the Institute for Cancer Research and Treatment, and Mauriziano 
Umberto I (Torino, Italy)18 were used in this study. 63 of 108 were KRAS, 
BRAF, NRAS and PI3KCA wild type quadruple negative (with wild-type 
KRas, NRas, PI3KCA, and B-Raf) based on matched next-generation 
sequencing analysis data from Bertotti et al. 9 and used for statistical 
analysis. Tumour tissues were implanted subcutaneously and passaged in 
NOD/SCID mice. Response data is available for each tumour to cetuximab 
treatment after 3 and 6 weeks19.
Reverse phase protein array
Protein was extracted from PDX tumour tissue and cell line standards and 
RPPA was performed as described previously20. Protein lysates 
normalized to 1μg/μL concentration as assessed by bicinchoninic acid 
assay (BCA, Biorad). Reverse phase protein array (RPPA) with a panel of 
antibodies targeting various key cancer related proteins was used for 
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measuring protein levels in untreated tumours. The response is form 
matching samples of same tumour in different mice. The DAKO 
(Carpinteria, CA) catalyzed signal amplification system was used for 
antibody blotting.
PDX Protein clustering
RPPA data for 93 PDX samples have been clustered using consensus 
Non-negative Matrix Factorization (R package ‘NMF’21, version 0.21.0) on 
centred RPPA data22, 23. NMF was performed 1 000 times with the number 
of clusters k varying from 2 to 8. k = 3 was selected based on visual 
inspection of co-clustering matrices and heatmap of clustered RPPA data.
To represent graphically the correspondence between CRIS subtypes 
classifiers and the RPPA clusters or cetuximab response, Factorial 
Correspondence Analysis (FCA) was used. For each comparison, χ2 
independence test was carried out. In order to have large enough 
numbers in the contingency table so that the χ2 approximation is correct, 
we combined together the closest CRIS subtypes.
DR MOMP, APOPTO-CELL and proliferation signature
The normalised gene expression of BIRC5, CCNB1, CDC20, CDCA1, 
CEP55, NDC80, MKI67, PTTG1, RRM2, TYMS and UBE2C was averaged 
and used as proliferation signature24, 25 of each PDX. The gene expression 
data for respective PDX models was downloaded from GSE7640213.
To calculate the sensitivity of patients' cancer cells to undergo apoptosis, 
the mathematical models APOPTO-CELL26 and DR_MOMP16 were 
applied, using PRO-CASPASE-3, PRO-CASPASE-9, SMAC, and XIAP 
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protein for APOPTO-CELL, and BAK, BAX, BCL2 and BCL(X)L for 
DR_MOMP as input for the models. MCL1 protein levels were assumed to 
be 0 nM for DR_MOMP. SMAC concentrations were assumed to be 122.7 
nM for APOPTO-CELL26. Protein levels were normalized to HeLa cells that 
were placed on the RPPA together with the cancer tissue16, 26.
Statistical analysis
Statistical analysis of RPPA data was done using ‘SAMR’27 (Significance 
Analysis of Microarrays, version 3.0) and ‘PAMR’28 (Prediction Analysis for 
Microarrays; version 1.56.1) R Packages (R version 3.6.2). LASSO was 
performed using the ‘glmnet’ R package (version 2.0-18). The packages 
‘ComplexHeatmap’29 (version 2.1.0) and ‘Circlize’30 (version 0.4.7) were 
used to create Figure 1. Week 3 response was used for all the statistical 
analysis as not all the mice were followed through after 3 weeks. Student’s 
t-test and ANOVA was used for measuring statistical significance. ANOVA 
was followed by Tukey's HSD (honest significant difference) test for 
multiple pair comparison. Fisher’s exact test was used for count data.
Results
Characterisation of KRAS, BRAF, NRAS and PI3KCA wild 
type metastatic CRC (phospho)protein signatures
To investigate cetuximab responses in patients with metastatic CRC, we 
analyzed a large collection of genomically annotated PDX models, for 
which information on response to cetuximab in mice was available18. Of 
the 108 patient-derived xenografts (PDX) ‘KRAS wild-type’ models 
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originally collected (determined by Sanger sequencing), 63 samples were 
identified to bear no somatic sequence alteration of the KRAS, NRAS, 
BRAF and PIK3CA genes as identified by exome sequencing with an 
average coverage within the target regions of nearly 150-fold for each 
sample 9. Protein levels were quantitatively profiled by Reverse Phase 
Protein Array (RPPA) analysis of fresh-frozen pre-treatment tumour 
samples derived from each PDX model (Figure 1A; Supplementary Table 
1).
To explore whether cetuximab responses were related to differences in 
cell signalling pathways as evaluated by RPPA (phospho)protein analysis, 
we first performed unsupervised clustering using Nonnegative Matrix 
Factorizations (NMF) of the 63 quadruple negative samples 
(Supplementary Table 2). Clustering identified three distinct protein 
clusters termed C1, C2 and C3 (Figure 1A). We also performed clustering 
in all n = 93 KRAS wild type samples and found 88.9% consistency of the 
clusters (Supplementary Table 1).
Protein cluster C1 contained 35 PDX models of which 13 were regressing, 
14 showed no change in volume, and 8 were progressing at week 3 
(Figure 1B). Samples in C1 had predominantly high levels of 
phosphorylated Chk-1 (S345), c-RAF (S338), S6 Ribosomal Protein 
(S235/236 and S240/244), Gab-1 (Y627) and GSK-3β (S9; Figure 1A and 
Supplementary Figure 1). In contrast, C1 samples had low levels of 
phosphorylated p38 MAPK (T180/Y182), AMPK (T172), FAK (Y925), Src 
(Y527), and Src (Y416). Furthermore, samples had low levels of SMAC, 
BCL(X) and STAT3 proteins.
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Cluster C2 contained 18 PDXs of which 4 were regressing, 10 showed no 
change in volume, and 4 were progressing after cetuximab treatment 
(Figure 1B). C2 tissues were characterised by high levels of 
phosphorylated EGFR (Y1068), BCL2 (S70 and T56), Src (Y527), and 
STAT3 (Y705) (Figure 1A and Supplementary Figure 1). Furthermore, the 
cluster had low p27 and PTEN levels. This cluster was also characterised 
by low levels of phosphorylated GSK-3β (S9), MAPK (T202/Y204) and 
MEK1/2 (S217/221).
Interestingly, cluster C3 contained no progressing tumour models, 6 with 
no change in volume and 4 regressing PDX models (Figure 1B). C3 
tissues had high levels of phosphorylated p38 MAPK (T180/Y182), AKT 
(S473), MEK1/2 (S217/221), MAPK (T202/Y204) and PDK1 (S241), 
together with high levels of p70 S6 Kinase and p27 protein levels (Figure 
1A and Supplementary Figure 1). Compared to clusters C1 and C2, C3 
showed low IGFI-Rβ, PARP, cIAP-1, APAF-1 and EGFR protein levels, 
together with low levels of cleaved caspase 9 (D330).
There was no difference in genetic alterations between the clusters (not 
shown). Overall, TP53 mutations were found in 90% (n = 57; from 89% in 
C1 to 94% in C2), APC mutations in 89% (n = 56; from 89% in C1 to 90% 
in C3) and TTN mutations in 48% (n = 30; from 40% in C1 to 70% in C3) 
of PDX models (genetic data from Bertotti et al.9). Further, we did not find 
protein clusters to be significantly associated with a specific CRIS 
molecular subtype (Figure 1C). C1 consisted of 4 CRIS-A, 7 CRIS-B, 16 
CRIS- C, 5 CRIS-D and 3 CRIS- E. C2 consisted of 2 CRIS-A, 3 CRIS-B, 
16 CRIS-C, 3 CRIS-D and 4 CRIS-E. C3 consisted of zero CRIS-A, 1 
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CRIS-B, 7 CRIS-C, 1 CRIS-D and 1 CRIS-E. Likely due to the small size 
of the tested collection, we did not find significant differences in response 
relative to the CRIS subtypes (Fisher’s exact p = 0.49; Figure 1D).
Identification of a (phospho)protein signature predicting 
responses to cetuximab
In a subsequent analysis we used a statistical method for class prediction 
from gene expression data using nearest shrunken centroids (prediction 
analysis for microarrays; PAM)28 to determine to what extent proteins were 
either up- or down-regulated in all PDX models when grouped according to 
their response to cetuximab at week 3 (Figure 2; Supplementary Table 3). 
Overall, proteins levels were found to be inverted when comparing 
regressing models with progressing models. Progressing tumour models 
had high levels of phosphorylated EGFR (Y1173 and Y1068), AKT (S373), 
S6 ribosomal protein (S235/236 and S240/244), HER3 (Y1289), cRAF 
(S338), Gab-1 (Y627) and BCL2 (T56), together with high protein levels of 
cIAP-1, IGFI-Rβ, PARP, BAK, BAX, EGFR and APAF-1 compared to 
regressing models. In contrast, levels of phosphorylated PDK1 (S241), 
Shc (Y317), STAT3 (Y705), FAK (Y925), phosphorylated GSK-3β (S9), 
Src (Y416), MAPK (T202/Y204), NF-κB-p65 (S536), Caspase-8, p27, Src, 
Xiap and SMAC were low in progressing compared to regressing models. 
When comparing responses at week 6, we observed high levels of AKT 
(S473), HIAP-2 and PARP, and low p27 levels in progressing compared to 
regressing models (Supplementary Figure 2).
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Refinement of a (phospho)protein response score 
As a next step, we aimed to further reduce the number of proteins required 
for a predictive (phospho)protein signature. For this purpose we employed 
least absolute shrinkage and selection operator (LASSO; L1 
regularization) and binominal logistic regression (progression versus 
regression) to identify the variables strongest associated with treatment 
response from the markers identified above. The advantage of LASSO is 
that the method exploits sparsity by shrinking less important features’ 
coefficients to zero. Using only progressing (n = 12) or regressing (n = 22) 
PDX models, LASSO reduced the required proteins to 22 markers (Figure 
3AB): PDK1 (S241; β = 2.4687), Caspase-8 (β = 2.3486), Shc (Y317; β = 
0.2415), Stat3 (Y705; β = 1.4916), p27 (β = 1.5234), XIAP (β = 0.2372), 
GSK-3β (S9; β = 1.3425), PI3-Kinase p110α (β = 0.4648), HER3 (β = 
0.2071), cleaved Caspase-9 (D330; β = 0.0043), MAPK - ERK 1/2 (β = 
0.2350) and PKC-alpha (S657; β = 0.9340) were found with a positive 
coefficient (Figure 3B). BAK (β = -1.6263), EGFR (Y1068; β = -0.1290), 
Akt (S473; β = -2.5973), S6 Ribosomal Protein (S240/244; β = -1.6658), 
HER3 (Y1289; β = -1.9349), mTOR (β = -1.600), NF-B-p65 (S536; β = -
1.9424), Gab-1 (Y627; β = -1.5928) and Bcl-2 (T56; β = -0.5066) were 
found with a negative coefficient (Figure 3B). The interception was 2.2000. 
To gain a deeper understanding of the role of these markers, we used the 
Spearman correlation coefficients (Figure 3A) to construct a co-expression 
network (Figure 3B). While proteins such as EGFR (Y1068) and NF-B-
p65 (S536) had the same coefficient in the LASSO model and were co-
expressed, Shc (Y317), GSK-3β (S9), HER3, Caspase-8, PDK1 (S241), 
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BAK and mTOR had disagreeing signs. Assuming that co-expressed 
proteins fell in the same, active or respectively inactive, signalling pathway 
and hence conducted a similar signal, the disagreement in the coefficients’ 
sign suggested a critical difference of the proteins’ role in responses to 
cetuximab.
We then applied the regression model to the PDXs that showed no or only 
minor changes in tumour volume (n = 30), in order to test whether the 
model is able to define models with any increase in tumour volume as 
“progressing” (n = 16) or “regressing” (n = 14). Although this is a 
challenging task, the model identified 12 models as true “progressing” 
(true positive), 9 as true “regressing” (true negative), 5 “regressing” as 
“progressing” and 4 ”progressing” as “regressing” models. Hence the 
majority of marginally progressing or regressing PDXs were correctly 
identified by the regression model.
Comparison of pre- and post-treatment protein profiles
In further exploratory analysis, we also investigated whether cetuximab 
treatment altered protein levels during treatment. We randomly selected 
15 PDX models, one from protein cluster C1, seven from cluster C2 and 
seven from cluster C3. Protein quantification using RPPA were repeated 
for pre- and post-treatment tumour tissues on a separate RPPA run. The 
pre-treated PDX tissues had a mean correlation coefficient of 0.79 (25th - 
75th percentile = 0.74 – 0.85) compared with the post-treated tissues 
(Supplementary Figure 3). Pairwise comparison of pre- and post-treatment 
samples showed that 6 out of 69 (phospho)proteins were significantly 
altered by more (or less) than factor 2 (or ½) in response to cetuximab. 
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Levels of phosphorylated Gab-1 (Y627; p < 0.001), MEK1/2 (S217/221; p 
< 0.001), p70 S6 kinase (T389; p < 0.001) and GSK-3β (S9; p < 0.01), 
together with levels of MEK1 (p < 0.001), cleaved Caspase-7 (D198; p < 
0.1) proteins, were significantly lower in post-treatment compared to pre-
treatment tissues (Figure 3C). The full list of changes in protein levels can 
be seen in Supplementary Table 4.
Levels of only 2 of the 6 proteins that were differential expressed were 
prognostic for the response to cetuximab when measured prior to 
treatment. Models not responding to cetuximab were more likely to lack 
Gab-1 (Y627) and GSK-3β (S9; Figure 2). Abundance of MEK1/2 
(S217/221) was characteristic for models of the protein cluster without 
progressing tumours (C3, Supplementary Figure 1). Levels of p70 S6 
kinase (T389; p < 0.001), MEK1 (p < 0.001) and cleaved Caspase-7 
(D198; p < 0.1) were neither associated with a specific response to 
cetuximab nor a protein cluster.
Proliferation rather than apoptosis systems score predicts 
responses to cetuximab
To determine whether apoptosis competence was a prognostic marker for 
anti-EGFR therapy responses, we used protein levels of BCL-2, BCL-XL, 
MCL-1, BAX, BAK, APAF1, SMAC, XIAP, PROCASPASE-3 and -9 in the 
63 PDX models as model inputs for two deterministic models of apoptosis 
competence, one describing the process of mitochondrial 
permeabilization, DR_MOMP16, and one the process of caspase activation 
downstream of mitochondrial permeabilization, APOPTO-CELL26 (Figure 
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4A). Both models were developed and validated by our group and 
previously shown to be prognostic for survival of stage 2 and 3 CRC 
patients16, 17, 31. DR_MOMP calculates the ‘stress dose’ of tumour cells 
required to undergo mitochondrial permeabilisation, with low values 
indicating a high apoptosis competence16. For quantitative evaluation of 
protein levels, cell lysates of the PDX models were normalized to lysates 
of HeLa cells in which absolute protein levels were previously determined 
by quantitative Western blotting using purified proteins16, 26. The mean 
levels of the proteins required as model inputs are shown in Figure 4BC. 
Employing DR_MOMP using the generated quantitative protein profiles, 
we determined a mean ‘stress dose’ of 171.4 nM (SD 56.4 nM) across all 
PDXs. PDXs with a ‘stress dose’ greater than the mean also had 
significantly less cleaved caspase 9 (D330) compared to models with 
‘stress dose’ less than the mean (t-test p < 0.01), confirming impaired 
apoptosis in models with high DR_MOMP ‘stress dose’ values. However, 
the DR_MOMP score did not correlate with cetuximab responses (ANOVA 
p = 0.6; Figure 4E). The DR_MOMP apoptosis score was lowest in PDX 
models in cluster C1 (mean = 152.9 nM) and, greatest in C3 (mean = 
246.0 nM; ANOVA p < 0.0001, Tukey post-hoc p ≤ 0.02; Figure 4F). There 
were no significant differences in DR_MOMP apoptosis scores when 
PDXs were grouped based on the CRIS subtypes (ANOVA p = 0.6; Figure 
4G).
APOPTO-CELL predicts apoptosis susceptibility of cells by modelling 
activation of executioner caspases and cleavage of their downstream 
substrates26. Exceeding a threshold of 25% substrate cleavage within 300 
Page 15 of 63
John Wiley & Sons, Inc.































































minutes served in previous studies as a surrogate for the competence of 
cells to undergo executioner (caspase 3) activation, in line with previous 
single-cell imaging findings 26, 31. APOPTO-CELL identified 24 PDX 
samples with less than 25% predicted substrate cleavage and 36 models 
with more than 25 % predicted substrate cleavage. However the predicted 
substrate cleavage did not correlate with responses of the PDX models to 
cetuximab (Fisher’s exact p = 0.89; Figure 4E). Further, there was no 
significant difference in the number of PDXs with substrate cleavage less 
or greater than 25% between protein clusters C1-C3 (Fisher’s exact p = 
0.09) or CRIS subtypes (Fisher’s exact p = 0.85; Figures 4FG).
We also questioned whether apoptosis signalling contributed to cetuximab 
responses only in specific protein clusters/molecular subtypes. There was 
no significant differences between DR_MOMP ‘stress dose’ scores and 
treatment responses when PDX models broken down into the three protein 
clusters C1, C2 and C3 (ANOVA interaction p = 0.9) or into the CRIS 
subtypes (ANOVA interaction p = 0.9). Similarly, there was no significant 
differences between the APOPTO-CELL class and treatment responses 
after stratifying for the protein cluster or CRIS (not-adjusted Fisher’s exact 
p > 0.12). Collectively, these data suggest that BCL2-dependent 
mitochondrial apoptosis and caspase-3 activation does not play a major 
role in cetuximab responses.
Next, we calculated the individual proliferative capacity of each PDX using 
an 11 gene signature index24, 25 using existing gene expression profiles13. 
Numerically, proliferation indices were lowest in protein cluster C3, and 
highest in C2. Statistical analysis revealed no significantly differences 
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between protein clusters (ANOVA p = 0.1; Figure 4H). CRIS-D had 
significant higher indices compared to the CRIS-B molecular subtype 
(Tukey post-hoc p = 0.02) and C (Tukey post-hoc p < 0.001; ANOVA p = 
0.001). Across all PDXs, the proliferation index gradually increased from 
PDXs with regressing toward progressing responses to cetuximab 
(ANOVA p-value of 0.01, Figure 4
J). Progressing PDX models had higher proliferation indices compared to 
stable (Tukey post-hoc p = 0.01 and 0.03) or regressing PDX models 
(Tukey post-hoc p = 0.001 and 0.02) if adjusted for either CRIS (ANOVA p 
= 0.01) or protein clusters (ANOVA p = 0.02). Collectively, these data 
suggested that proliferation rather than apoptosis score is a key 
determinant of cetuximab responses in ‘quadruple negative’ metastatic 
CRC PDX models. 
We also condensed the cell death scores of DR_MOMP and APOPTO-
CELL and the proliferation score to an overall growth score by classifying 
models with impaired apoptosis and high proliferation as high growth (n = 
19), models with impeccable apoptosis competency and low proliferation 
as low growth (n = 6), and all other models as intermediate growth (n = 35; 
Figure 3K). Growths score did not reflect response to cetuximab with the 
PDX models being equally likely to show progression or regression in 
response to cetuximab (Fisher’s Exact p = 0.18; Figure 3L).
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Development of an improved (phospho)protein response 
score
Because our previous protein analysis identified cell death markers (Figure 
2 and 3B; BAK, BCL2, cleaved Caspase-9, XIAP, etc.) that indicated 
responses to cetuximab, we finally decided to repeat the LASSO analysis 
with the 22 proteins, but replaced the apoptosis-related markers (BAK, 
BCL-2 (T56), cleaved Caspase-9 (D330) and XIAP) with the normalised 
DR_MOMP score. In addition, we removed the protein markers for AKT, 
mTOR, MAPK-ERK1/2 and PI3-Kinase p110α based on the assumption 
that these markers will likely not indicate the activation status of their 
respective signalling pathway. This enabled us to reduce the overall 
number of proteins analysed. The LASSO analysis set only the coefficient 
of DR_MOMP to zero: PDK1 (S241; β = 6.3505), Caspase-8 (β = 5.2772), 
Shc (Y317; β = 4.2598), Stat3 (Y705; β = 2.6455), p27 (β = 0.6169), GSK-
3β (S9; β = 6.0001), HER3 (β = 3.5702) and PKC-alpha (S657; β = 
0.8191) were found with a positive coefficient. EGFR (Y1068; β = -1.065), 
Akt (S473; β = -5.5777), S6 Ribosomal Protein (S240/244; β = -4.3452), 
HER3 (Y1289; β = -5.4732), NF-kB-p65 (S536; β = -6.3106) and Gab-1 
(Y627; β = -4.6551) were found with a negative coefficients. The 
interception was 4.9424. The coefficients were in line with the first LASSO 
model (Spearman’s rank correlation rho = 0.88, p < 0.0001). Testing the 
updated regression model (14 markers) on PDX models showing no or 
only minor changes in tumour volume (n = 30), showed a significant 
improvement compared with the initial score, with 13 PDX models 
identified as true “progressing” (true positive), 10 as true “regressing” (true 
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negative), 4 “regressing” as “progressing” and 3 ”progressing” as 
“regressing” models.
Discussion
The discovery of new prognostic biomarkers for cetuximab response is of 
crucial importance for improving efficiency, and efficacy, of the treatment 
of metastatic CRC. The genetic heterogeneity of metastatic CRC cancer 
makes it unlikely that one single protein will serve as a biomarker in all 
instances, and high throughput techniques such as RPPA may therefore 
be helpful in identifying predictive biomarker sets. Statistical analysis of 
our RPPA data showed significant correlation between levels of 20 
(phospho)proteins with changes in tumour volume, as detected in PDX 
models. We identified markers indicating active signalling of the EGFR 
pathway such as EGFR (Y1068) itself and Akt (S473), Gab-1 (Y627), Shc 
(Y317), Stat3 (Y705) and PDK1 (S241) to significantly predict responses 
to cetuximab. Overall we found a high cross correlation between levels of 
these proteins markers across all samples, emphasising their potential to 
act as predictive biomarkers for cetuximab responses.
Interestingly, we found that high levels of phosphorylated EGFR at 
Tyr1068 and Akt at Ser473 indicated tumour progression, whereas 
regressing tumours showed a lack of phosphorylated Shc at Tyr317 and 
Stat3 at Tyr705. Phosphorylation of EGFR on Tyr1068 (and Tyr1086) 
leads to activation of the MAPK cascade and AKT activation32. Signal 
transducer and activator of transcription 3 (STAT3) and its phosphorylation 
are associated with cell growth and transformation33. The scaffolding 
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protein Src homology and collagen domain protein (Shc) directs the EGF 
stimuli to pro-mitogenic, pro-survival and invasion signalling pathways in a 
time-dependent manner34. Phosphoinositide Dependent Protein Kinase 1 
(PDK1) is a crucial enzyme in transducing signals to multiple effector 
pathways including phosphoinositide 3-kinase (PI3K/AKT), Ras/mitogen-
activated protein kinase (MAPK), serum/glucocorticoid regulated kinase 
(SGK), p70 ribosomal protein S6 kinase (p70 S6 K) and members of 
protein kinase C (PKC) family. Phosphorylation of PDK1 on Ser241 is 
necessary for its activation35. Some of its substrates require a prior 
conformational switch to allow subsequent phosphorylation by PDK135 
rendering it as gatekeeper for those signalling pathways. We also found 
that models expressing the human epidermal growth factor receptor 3 
(HER3, also EGFR3) were more likely to respond with tumour regression 
in response to cetuximab. In contrast, phosphorylation of HER3 on 
Tyr1289 was indicative for tumour progression. HER3 cannot be activated 
by ligand alone but its heterodimer with EGFR and HER2 is highly 
mitogenic36. Existing literature on the expression and relevance of HER3 is 
inconsistent, reporting association with either increased or decreased 
survival of CRC patients36. In advanced non-small cell lung cancer, 
abundant HER3 expression identifies gefitinib (EGFR inhibitor) sensitive 
cell lines37. In addition, Bosch-Vilaró et al.38 described a cetuximab-
induced feedback HER3 activation that reduces the response to 
cetuximab, and in pancreatic cancer, dimerization of EGFR and HER3 was 
reported to be necessary for downstream signalling39.
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Further LASSO and binominal logistic regression analysis of these protein 
biomarkers delivered a refined protein signatures for predicting responses 
to cetuximab. Given that many of the identified markers in our signature 
are predicted to regulate cell proliferation, we also investigated a 
previously published, transcriptome-based proliferation score as to its 
predictive power24, 25. Using this score, we also found a significant 
correlation between cetuximab responses and the transcriptome-based 
proliferation score across all 63 PDX models investigated. Although the 
focus of our study was the delivery of a (phospo)protein signature, 
combining our protein score with the transcriptome-based proliferation 
score did not further increase the predictive power  of the protein 
signature, suggesting that the signature was sufficient to describe the 
proliferation status of the PDX models in relation to cetuximab responses.
We also found that responses to cetuximab were dependent on protein 
clusters identified through unsupervised cluster analysis. One of the 
clusters, protein cluster 3 (C3), represented a cluster without progressing 
PDX models. C3 was characterised by PDK1-dependend active AKT 
signalling and inhibition of the cell cycle. The largest protein cluster (C1) in 
contrast showed mixed responses, and was characterised by genotoxic 
stress, inflammation and cell survival signalling. Cluster C2 was also 
composed of mixed responders and characterised by active EGFR 
signalling and inhibition of apoptosis. Compared to PDX models in C1 and 
C2, PDX models in C3 had lower levels of phosphorylated MEK1/2 
(S217/221). This suggests that cetuximab-resistant models in C1 and C2 
may potentially benefit from MEK inhibitors. We also explored the 
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relationship between protein clusters and transcriptome-based molecular 
subtypes. CRIS molecular subtypes capture very well differences in 
intrinsic tumour cell gene expression13. CRIS-C was previously associated 
with sensitivity to cetuximab13, potentially a consequence of the lower 
representation of KRAS and NRAS mutations in this subtype13. We did not 
find that any of the three protein clusters showed a significant association 
with CRIS molecular subtypes. We also found that, when focusing on 
KRAS, NRAS, BRAF and PIK3CA quadruple wild type models, CRIS-C 
was not enriched in cetuximab responders (Figure 1D). Overall, this 
suggests that sensitivity to anti-EGFR therapy is predicted well by an 
analysis of (phospho)protein clusters.
While we observed that increased proliferative capacity was associated 
with disease progression during cetuximab treatment (Figure 4J), 
competence to undergo mitochondrial apopotosis was not a major 
determinant of cetuximab responses. Both the DR_MOMP and APOPTO-
CELL apoptosis models have been shown to be prognostic for stage II and 
III CRC patients, but have not yet not been tested in the setting of 
metastatic CRC17, 31. 
Our data suggest that resistance to mitochondrial apoptosis is not critical 
for responses of metastatic CRC to cetuximab. While cetuximab was 
shown to induce apoptosis to a minor extent in colorectal cancer cells in 
previous studies40, combination therapy for example with regorafenib has 
been shown to be required for significant apoptosis induction by 
cetuximab41. In the setting of colorectal cancer, we have previously also 
shown that activation of Caspase-3 may be associated with a 
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compensatory stimulation of cancer cell proliferation and adverse effects 
on clinical outcome42. Here, we also observed that PDX models with 
progressing tumours tended to have higher levels cleaved Caspase-3 
compared to models with stable or regressing tumours (Figure 2). It might 
be possible that activating apoptosis may have both beneficial and 
detrimental effects in the setting of metastatic CRC.
By comparing matched pre- and post-treatment samples, we also found 
that levels of GSK-3β (S9) were reduced in tissue after cetuximab 
treatment. The Glycogen synthase kinase 3β (GSK-3β) is a key player in 
the β-catenin/Wnt signalling pathway but also phosphorylates various 
transcription factors and structural, metabolic and signalling proteins43, 44. 
Inhibition of GSK-3β activity by phosphorylation at Ser945 is a critical factor 
to allow many coupled signalling pathways to proceed43, 44. 96% of CRCs 
harbour increased oncogenic Wnt pathway alteration46 and dysregulation 
of GSK-3β signalling is associated with cancer and metabolic and 
degenerative disorders47. Inhibition of GSK-3β was reported to induce 
apoptosis and attenuated proliferation in colon cancer cells in vitro48 and in 
colon cancer xenografts49. It is possible that inhibition of GSK-3β would be 
desirable co-treatment with cetuxiumab. Lithium, which also acts as an 
inhibitor of GSK-3β50, was reported to supress cell proliferation in prostate 
cancer xenographs51 and may inhibit colon cancer metastatsis by blocking 
transforming growth factor-β-induced protein (TGFBIp) expression52 
downstream of GSK-353. Combining cetuximab with lithium or other GSK-
3 inhibitors may improve response to cetuximab.
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In conclusion, we present here a 14 (phospho)protein marker signature 
that was predicting responses to cetuximab in mCRC tissue. Likewise, our 
findings emphasises GSK-3β to be potentially targetable for a co-
treatment with cetuximab.
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Figure Legends
Figure 1
(A) Heatmap of protein levels determined by RPPA. PDX models were annotated 
with the, CRIS, the consensus protein cluster subtype, and response to cetuximab 
(top). Clustering was performed using Nonnegative Matrix Factorization (NMF) 
consensus clustering algorithm. The right annotations indicates proteins’ 
association to the protein clusters (Supplementary Figure 1). Chord diagrams show 
overlap between RPPA clusters and (B) response to cetuximab and (C) CRIS, and 
(D) overlap between CRIS and response to cetuximab.
Figure 2
Protein scores indicating proteins’ association to the PDX models’ response to 
cetuximab. Proteins’ scores for response to cetuximab after 3 week was calculated 
using PAM 27.
Figure 3
(A) Heatmap of Spearman’s rank correlation coefficients for proteins associated 
with differences in response to cetuximab from Figure 2. (B) Undirected graph of 
proteins found to be relevant in LASSO analysis. Intensity and colour of the edges 
indicate the correlation coefficient of (A). Grouping based on the signs of the 
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correlation coefficients and signs of the coefficients found by LASSO are indicated 
black & white nodes and plus & minus icons, respectively. (C) Protein found to be 
differential expressed in PDX models after treatment with cetuximab, based on 
pairwise comparison and Benjamin & Hochberg adjusted p-value. Dashed red lines 
indicate 0.05 significance threshold for p-value, and 2-fold or 1/2-fold protein level. 
The protein marker names and n-fold differences (treated to un-treated) in brackets 
were added for proteins passing all thresholds.
Figure 4
(A) Simplified illustration of the apoptotic signalling modelled in DR_MOMP and 
APOPTO-CELL. Absolute protein levels normalised to HeLa cells were measured 
using RPPA and used as input for (B) DR_MOMP and (C) APOPTO-CELL. 
Calculated DR MOMP values against (D) APOPTO-CELLs’ calculated substrate 
cleavage class with (E) differences in response to cetuximab, (F) RPPA protein 
cluster C3 and (G) CRIS. Calculated proliferation against (H) protein clusters, (I) 
CRIS and (J) response to cetuximab. (K) The proliferation score was combined with 
both models to a tumour growth score. (L) n-numbers of tumour growth score 
classes against response to cetuximab, RPPA protein cluster and CRIS.
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Novelty and Impact: A large fraction of patients with metastatic colorectal cancer do 
not respond to anti-EGFR therapy despite KRAS wild type tumours. Statistical 
analysis of RPPA data of colorectal cancer KRAS, BRAF, NRAS and PI3KCA wild 
type PDX models revealed a 14 - 20 (phospho)protein signature that was predicting 
responses to cetuximab. Our findings furthermore emphasise GSK-3β to be 
potentially targetable for a co-treatment with cetuximab.
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Antibodies targeting the human epidermal growth factor receptor (EGFR) are used 
for the treatment of RAS wild-type metastatic colorectal cancer. A significant 
proportion of patients remains unresponsive to this therapy. Here, we performed a 
reverse phase protein array-based (phospho)protein analysis of 63 KRAS, NRAS, 
BRAF and PIK3CA wild-type metastatic CRC tumours. Responses of tumours to 
anti-EGFR therapy with cetuximab were recorded in patient-derived xenograft (PDX) 
models. Unsupervised hierarchical clustering of pre-treatment tumour tissue 
identified three clusters, of which cluster C3 was exclusively composed of 
responders. Clusters C1 and C2 showed mixed responses. None of the three protein 
clusters showed a significant correlation with transcriptome-based subtypes. 
Analysis of protein signatures across all PDXs identified 14 markers that 
discriminated cetuximab-sensitive and -resistant tumours: PDK1 (S241), Caspase-8, 
Shc (Y317), Stat3 (Y705), p27, GSK-3β (S9), HER3, PKC- (S657), EGFR (Y1068), 
Akt (S473), S6 Ribosomal Protein (S240/244), HER3 (Y1289), NF-B-p65 (S536) 
and Gab-1 (Y627). Least absolute shrinkage and selection operator and binominal 
logistic regression analysis delivered refined protein signatures for predicting 
response to cetuximab. (Phospo-)protein analysis of matched pre- and post-treated 
models furthermore showed significant reduction of Gab-1 (Y627) and GSK-3β (S9) 
exclusively in responding models, suggesting novel targets for treatment.
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Colorectal cancer (CRC) is the third and second most commonly 
diagnosed cancer in males and females, and the second most common 
cause of cancer-related deaths in the developed world. In the advanced 
setting, CRC is routinely treated with fluorouracil (5-FU)-based 
chemotherapy. 30% of CRC patients present in the metastatic setting1 
where response rates to palliative 5-FU/oxaliplatin- or 5-FU/irinotecan-
based chemotherapy range between 40-50%. Median overall survival 
remains poor at around 16-19 months2. Identifying the importance of 
epidermal growth factor (EGF) signalling for the survival of CRC cells 
resulted in the development of targeted therapies that neutralize the 
oncogenic activity of EGF receptors (EGFR). Anti-EGFR therapies have 
significantly improved survival in metastatic CRC patients3. Guidelines 
recommend to test for KRAS, NRAS and BRAF mutations as well as 
microsatellite instability status in CRC patients being considered for anti-
EGFR therapy4, 5 on the bases of the ineffectiveness of anti-EGFR therapy 
in patients with activating KRAS, BRAF, and NRAS mutations6, and 
favourable responses to immune check point inhibitors in microsatellite 
instability-high patients4. While PI3KCA mutational analysis is not 
recommended yet4, PIK3CA exon 20 mutations were linked with a worse 
outcome compared with wild-type status in patients with metastatic 
colorectal cancer7. Nevertheless, between 50–60% of patients will not 
benefit from anti-EGFR treatment even when these are KRAS, BRAF, 
NRAS and PI3KCA wild type7.
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Mutations and copy number alterations in genes encoding for other 
survival signaling proteins have been shown to contribute to anti-EGFR 
resistance. For example, HER2-amplification, IGF2 overexpression or 
increased MET activity resulted in reduced responses to anti-EGFR 
therapy, as demonstrated in patient-derived xenograft (PDX) models of 
metastatic CRC and in patients8, 9. Analysis of the genomic and 
transcriptomic landscape of anti-EGFR resistance in PDX models and 
patients furthermore identified mutations in EGFR, FGFR1, PDGFRA, and 
MAP2K1 or loss of NF1 to contribute to anti-EGF resistance9, 10.
While identification of patient-specific genome alterations provides a 
personalised diagnosis that provides insights into anti-EGFR therapy 
responses and may open opportunities for personalised therapies, 
interpretation of often multiple genomic alterations found in most patients 
is not always straightforward. Other efforts to identify responders and non-
responders to anti-EGFR therapy have therefore focussed on the power of 
unsupervised molecular subtyping of tumours. An international meta-
analysis and bioinformatics effort led to the identification of four distinct 
subtypes in CRC, termed ‘Consensus Molecular Subtypes’ (CMS1-
CMS4)11. A recent study demonstrated that CMS2 patients benefitted 
more from anti-EGFR therapy than patients treated with anti-angiogenic 
therapy, while the opposite was the case in CMS1 patients12. However 
predictions of anti-EGFR therapy responses in CMS3 and CMS4 patients 
were not possible, and significant variability in overall and progression free 
survival are still seen across all four CMS subtypes. Because stroma-
derived mRNAs in whole tumour transcriptomes may obscure 
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transcriptional features displayed by cancer cells, other efforts leveraged 
the power of patient-derived mouse xenograft (PDX) models in which 
human stroma is replaced by mouse stroma to obtain five CRC ‘intrinsic’ 
(CRIS) molecular subtypes, termed CRIS-A to E13. CRIS-C was identified 
as a subtype associated with EGFR signalling and increased sensitivity to 
anti-EGFR therapy. However responses to anti-EGFR therapy strongly 
varied among the other four CRIS subtypes13.
EGFR activation results in the activation of several downstream signalling 
pathways, including the PI3K/AKT and MAPK pathways14. The activation 
status of these key signalling pathways influences a variety of biological 
processes such as proliferation, apoptosis, cell migration, bioenergetics, 
immune responses, and angiogenesis. A different approach to investigate 
responses to anti-EGFR therapy is to determine the activation status of 
key signalling branches activated by EGFR receptors and their 
downstream effectors, supported by statistical or deterministic modelling15. 
Because processes such as proliferation and apoptosis are controlled by 
complex networks that show significant signalling redundancies, 
deterministic systems models have been developed to estimate more 
precisely proliferative capacity or apoptosis sensitivity of tumours. One 
such tool developed by our group is the systems model, DR_MOMP, 
which calculates the apoptosis sensitivity of tumours based on a 
quantitative analysis of BCL-2 family proteins and their interactions16, 17. 
To identify novel prognostic markers of anti-EGFR therapy, we here 
comprehensively profiled 83 signalling proteins and (phospho)proteins 
related to EGFR and key cancer signalling pathways in a cohort of 63 
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KRAS, BRAF, NRAS and PI3KCA wild type PDX models isolated from 
liver biopsies that were derived from metastatic CRC patients9, 18. We 
performed both statistical and systems modelling analyses to identify novel 
protein signatures of anti-EGFR responsiveness.
Methods
CRC PDX in vivo model 
108 PDX models derived from colorectal cancer liver metastasis originally 
at the Institute for Cancer Research and Treatment, and Mauriziano 
Umberto I (Torino, Italy)18 were used in this study. 63 of 108 were KRAS, 
BRAF, NRAS and PI3KCA wild type based on matched next-generation 
sequencing analysis data from Bertotti et al. 9 and used for statistical 
analysis. Tumour tissues were implanted subcutaneously and passaged in 
NOD/SCID mice. Response data is available for each tumour to cetuximab 
treatment after 3 and 6 weeks19.
Reverse phase protein array
Protein was extracted from PDX tumour tissue and cell line standards and 
RPPA was performed as described previously20. Protein lysates 
normalized to 1μg/μL concentration as assessed by bicinchoninic acid 
assay (BCA, Biorad). Reverse phase protein array (RPPA) with a panel of 
antibodies targeting various key cancer related proteins was used for 
measuring protein levels in untreated tumours. The response is form 
matching samples of same tumour in different mice. The DAKO 
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(Carpinteria, CA) catalyzed signal amplification system was used for 
antibody blotting.
PDX Protein clustering
RPPA data for 93 PDX samples have been clustered using consensus 
Non-negative Matrix Factorization (R package ‘NMF’21, version 0.21.0) on 
centred RPPA data22, 23. NMF was performed 1 000 times with the number 
of clusters k varying from 2 to 8. k = 3 was selected based on visual 
inspection of co-clustering matrices and heatmap of clustered RPPA data.
To represent graphically the correspondence between CRIS subtypes 
classifiers and the R PA clusters or cetuximab response, Factorial 
Correspondence Analysis (FCA) was used. For each comparison, χ2 
independence test was carried out. In order to have large enough 
numbers in the contingency table so that the χ2 approximation is correct, 
we combined together the closest CRIS subtypes.
DR MOMP, APOPTO-CELL and proliferation signature
The normalised gene expression of BIRC5, CCNB1, CDC20, CDCA1, 
CEP55, NDC80, MKI67, PTTG1, RRM2, TYMS and UBE2C was averaged 
and used as proliferation signature24, 25 of each PDX. The gene expression 
data for respective PDX models was downloaded from GSE7640213.
To calculate the sensitivity of patients' cancer cells to undergo apoptosis, 
the mathematical models APOPTO-CELL26 and DR_MOMP16 were 
applied, using PRO-CASPASE-3, PRO-CASPASE-9, SMAC, and XIAP 
protein for APOPTO-CELL, and BAK, BAX, BCL2 and BCL(X)L for 
DR_MOMP as input for the models. MCL1 protein levels were assumed to 
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be 0 nM for DR_MOMP. SMAC concentrations were assumed to be 122.7 
nM for APOPTO-CELL26. Protein levels were normalized to HeLa cells that 
were placed on the RPPA together with the cancer tissue16, 26.
Statistical analysis
Statistical analysis of RPPA data was done using ‘SAMR’27 (Significance 
Analysis of Microarrays, version 3.0) and ‘PAMR’28 (Prediction Analysis for 
Microarrays; version 1.56.1) R Packages (R version 3.6.2). LASSO was 
performed using the ‘glmnet’ R package (version 2.0-18). The packages 
‘ComplexHeatmap’29 (version 2.1.0) and ‘Circlize’30 (version 0.4.7) were 
used to create Figure 1. Week 3 response was used for all the statistical 
analysis as not all the mice were followed through after 3 weeks. Student’s 
t-test and ANOVA was used for measuring statistical significance. ANOVA 
was followed by Tukey's HSD (honest significant difference) test for 
multiple pair comparison. Fisher’s exact test was used for count data.
Results
Characterisation of KRAS, BRAF, NRAS and PI3KCA wild 
type metastatic CRC (phospho)protein signatures
To investigate cetuximab responses in patients with metastatic CRC, we 
analyzed a large collection of genomically annotated PDX models, for 
which information on response to cetuximab in mice was available18. Of 
the 108 patient-derived xenografts (PDX) ‘KRAS wild-type’ models 
originally collected (determined by Sanger sequencing), 63 samples were 
identified to bear no somatic sequence alteration of the KRAS, NRAS, 
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BRAF and PIK3CA genes as identified by exome sequencing with an 
average coverage within the target regions of nearly 150-fold for each 
sample 9. Protein levels were quantitatively profiled by Reverse Phase 
Protein Array (RPPA) analysis of fresh-frozen pre-treatment tumour 
samples derived from each PDX model (Figure 1A; Supplementary Table 
1).
To explore whether cetuximab responses were related to differences in 
cell signalling pathways as evaluated by RPPA (phospho)protein analysis, 
we first performed unsupervised clustering using Nonnegative Matrix 
Factorizations (NMF) of the 63 quadruple negative samples 
(Supplementary Table 2). Clustering identified three distinct protein 
clusters termed C1, C2 and C3 (Figure 1A). We also performed clustering 
in all n = 93 KRAS wild type samples and found 88.9% consistency of the 
clusters (Supplementary Table 1).
Protein cluster C1 contained 35 PDX models of which 13 were regressing, 
14 showed no change in volume, and 8 were progressing at week 3 
(Figure 1B). Samples in C1 had predominantly high levels of 
phosphorylated Chk-1 (S345), c-RAF (S338), S6 Ribosomal Protein 
(S235/236 and S240/244), Gab-1 (Y627) and GSK-3β (S9; Figure 1A and 
Supplementary Figure 1). In contrast, C1 samples had low levels of 
phosphorylated p38 MAPK (T180/Y182), AMPK (T172), FAK (Y925), Src 
(Y527), and Src (Y416). Furthermore, samples had low levels of SMAC, 
BCL(X) and STAT3 proteins.
Cluster C2 contained 18 PDXs of which 4 were regressing, 10 showed no 
change in volume, and 4 were progressing after cetuximab treatment 
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(Figure 1B). C2 tissues were characterised by high levels of 
phosphorylated EGFR (Y1068), BCL2 (S70 and T56), Src (Y527), and 
STAT3 (Y705) (Figure 1A and Supplementary Figure 1). Furthermore, the 
cluster had low p27 and PTEN levels. This cluster was also characterised 
by low levels of phosphorylated GSK-3β (S9), MAPK (T202/Y204) and 
MEK1/2 (S217/221).
Interestingly, cluster C3 contained no progressing tumour models, 6 with 
no change in volume and 4 regressing PDX models (Figure 1B). C3 
tissues had high levels of phosphorylated p38 MAPK (T180/Y182), AKT 
(S473), MEK1/2 (S217/221), MAPK (T202/Y204) and PDK1 (S241), 
together with high levels of p70 S6 Kinase and p27 protein levels (Figure 
1A and Supplementary Figure 1). Compared to clusters C1 and C2, C3 
showed low IGFI-Rβ, PARP, cIAP-1, APAF-1 and EGFR protein levels, 
together with low levels of cleaved caspase 9 (D330).
There was no difference in genetic alterations between the clusters (not 
shown). Overall, TP53 mutations were found in 90% (n = 57; from 89% in 
C1 to 94% in C2), APC mutations in 89% (n = 56; from 89% in C1 to 90% 
in C3) and TTN mutations in 48% (n = 30; from 40% in C1 to 70% in C3) 
of PDX models (genetic data from Bertotti et al.9). Further, we did not find 
protein clusters to be significantly associated with a specific CRIS 
molecular subtype (Figure 1C). C1 consisted of 4 CRIS-A, 7 CRIS-B, 16 
CRIS- C, 5 CRIS-D and 3 CRIS- E. C2 consisted of 2 CRIS-A, 3 CRIS-B, 
16 CRIS-C, 3 CRIS-D and 4 CRIS-E. C3 consisted of zero CRIS-A, 1 
CRIS-B, 7 CRIS-C, 1 CRIS-D and 1 CRIS-E. Likely due to the small size 
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of the tested collection, we did not find significant differences in response 
relative to the CRIS subtypes (Fisher’s exact p = 0.49; Figure 1D).
Identification of a (phospho)protein signature predicting 
responses to cetuximab
In a subsequent analysis we used a statistical method for class prediction 
from gene expression data using nearest shrunken centroids (prediction 
analysis for microarrays; PAM)28 to determine to what extent proteins were 
either up- or down-regulated in all PDX models when grouped according to 
their response to cetuximab at week 3 (Figure 2; Supplementary Table 3). 
Overall, proteins levels were found to be inverted when comparing 
regressing models with progressing models. Progressing tumour models 
had high levels of phosphorylated EGFR (Y1173 and Y1068), AKT (S373), 
S6 ribosomal protein (S235/236 and S240/244), HER3 (Y1289), cRAF 
(S338), Gab-1 (Y627) and BCL2 (T56), together with high protein levels of 
cIAP-1, IGFI-Rβ, PARP, BAK, BAX, EGFR and APAF-1 compared to 
regressing models. In contrast, levels of phosphorylated PDK1 (S241), 
Shc (Y317), STAT3 (Y705), FAK (Y925), phosphorylated GSK-3β (S9), 
Src (Y416), MAPK (T202/Y204), NF-κB-p65 (S536), Caspase-8, p27, Src, 
Xiap and SMAC were low in progressing compared to regressing models. 
When comparing responses at week 6, we observed high levels of AKT 
(S473), HIAP-2 and PARP, and low p27 levels in progressing compared to 
regressing models (Supplementary Figure 2).
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Refinement of a (phospho)protein response score 
As a next step, we aimed to further reduce the number of proteins required 
for a predictive (phospho)protein signature. For this purpose we employed 
least absolute shrinkage and selection operator (LASSO; L1 
regularization) and binominal logistic regression (progression versus 
regression) to identify the variables strongest associated with treatment 
response from the markers identified above. The advantage of LASSO is 
that the method exploits sparsity by shrinking less important features’ 
coefficients to zero. Using only progressing (n = 12) or regressing (n = 22) 
PDX models, LASSO reduced the required proteins to 22 markers (Figure 
3AB): PDK1 (S241; β = 2.4687), Caspase-8 (β = 2.3486), Shc (Y317; β = 
0.2415), Stat3 (Y705; β = 1.4916), p27 (β = 1.5234), XIAP (β = 0.2372), 
GSK-3β (S9; β = 1.3425), PI3-Kinase p110α (β = 0.4648), HER3 (β = 
0.2071), cleaved Caspase-9 (D330; β = 0.0043), MAPK - ERK 1/2 (β = 
0.2350) and PKC-alpha (S657; β = 0.9340) were found with a positive 
coefficient (Figure 3B). BAK (β = -1.6263), EGFR (Y1068; β = -0.1290), 
Akt (S473; β = -2.5973), S6 Ribosomal Protein (S240/244; β = -1.6658), 
HER3 (Y1289; β = -1.9349), mTOR (β = -1.600), NF-B-p65 (S536; β = -
1.9424), Gab-1 (Y627; β = -1.5928) and Bcl-2 (T56; β = -0.5066) were 
found with a negative coefficient (Figure 3B). The interception was 2.2000. 
To gain a deeper understanding of the role of these markers, we used the 
Spearman correlation coefficients (Figure 3A) to construct a co-expression 
network (Figure 3B). While proteins such as EGFR (Y1068) and NF-B-
p65 (S536) had the same coefficient in the LASSO model and were co-
expressed, Shc (Y317), GSK-3β (S9), HER3, Caspase-8, PDK1 (S241), 
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BAK and mTOR had disagreeing signs. Assuming that co-expressed 
proteins fell in the same, active or respectively inactive, signalling pathway 
and hence conducted a similar signal, the disagreement in the coefficients’ 
sign suggested a critical difference of the proteins’ role in responses to 
cetuximab.
We then applied the regression model to the PDXs that showed no or only 
minor changes in tumour volume (n = 30), in order to test whether the 
model is able to define models with any increase in tumour volume as 
“progressing” (n = 16) or “regressing” (n = 14). Although this is a 
challenging task, the model identified 12 models as true “progressing” 
(true positive), 9 as true “regressing” (true negative), 5 “regressing” as 
“progressing” and 4 ”progressing” as “regressing” models. Hence the 
majority of marginally progressing or regressing PDXs were correctly 
identified by the regression model.
Comparison of pre- and post-treatment protein profiles
In further exploratory analysis, we also investigated whether cetuximab 
treatment altered protein levels during treatment. We randomly selected 
15 PDX models, one from protein cluster C1, seven from cluster C2 and 
seven from cluster C3. Protein quantification using RPPA were repeated 
for pre- and post-treatment tumour tissues on a separate RPPA run. The 
pre-treated PDX tissues had a mean correlation coefficient of 0.79 (25th - 
75th percentile = 0.74 – 0.85) compared with the post-treated tissues 
(Supplementary Figure 3). Pairwise comparison of pre- and post-treatment 
samples showed that 6 out of 69 (phospho)proteins were significantly 
altered by more (or less) than factor 2 (or ½) in response to cetuximab. 
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Levels of phosphorylated Gab-1 (Y627; p < 0.001), MEK1/2 (S217/221; p 
< 0.001), p70 S6 kinase (T389; p < 0.001) and GSK-3β (S9; p < 0.01), 
together with levels of MEK1 (p < 0.001), cleaved Caspase-7 (D198; p < 
0.1) proteins, were significantly lower in post-treatment compared to pre-
treatment tissues (Figure 3C). The full list of changes in protein levels can 
be seen in Supplementary Table 4.
Levels of only 2 of the 6 proteins that were differential expressed were 
prognostic for the response to cetuximab when measured prior to 
treatment. Models not responding to cetuximab were more likely to lack 
Gab-1 (Y627) and GSK-3β (S9; Figure 2). Abundance of MEK1/2 
(S217/221) was characteristic for models of the protein cluster without 
progressing tumours (C3, Supplementary Figure 1). Levels of p70 S6 
kinase (T389; p < 0.001), MEK1 (p < 0.001) and cleaved Caspase-7 
(D198; p < 0.1) were neither associated with a specific response to 
cetuximab nor a protein cluster.
Proliferation rather than apoptosis systems score predicts 
responses to cetuximab
To determine whether apoptosis competence was a prognostic marker for 
anti-EGFR therapy responses, we used protein levels of BCL-2, BCL-XL, 
MCL-1, BAX, BAK, APAF1, SMAC, XIAP, PROCASPASE-3 and -9 in the 
63 PDX models as model inputs for two deterministic models of apoptosis 
competence, one describing the process of mitochondrial 
permeabilization, DR_MOMP16, and one the process of caspase activation 
downstream of mitochondrial permeabilization, APOPTO-CELL26 (Figure 
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4A). Both models were developed and validated by our group and 
previously shown to be prognostic for survival of stage 2 and 3 CRC 
patients16, 17, 31. DR_MOMP calculates the ‘stress dose’ of tumour cells 
required to undergo mitochondrial permeabilisation, with low values 
indicating a high apoptosis competence16. For quantitative evaluation of 
protein levels, cell lysates of the PDX models were normalized to lysates 
of HeLa cells in which absolute protein levels were previously determined 
by quantitative Western blotting using purified proteins16, 26. The mean 
levels of the proteins required as model inputs are shown in Figure 4BC. 
Employing DR_MOMP using the generated quantitative protein profiles, 
we determined a mean ‘stress dose’ of 171.4 nM (SD 56.4 nM) across all 
PDXs. PDXs with a ‘stress dose’ greater than the mean also had 
significantly less cleaved caspase 9 (D330) compared to models with 
‘stress dose’ less than the mean (t-test p < 0.01), confirming impaired 
apoptosis in models with high DR_MOMP ‘stress dose’ values. However, 
the DR_MOMP score did not correlate with cetuximab responses (ANOVA 
p = 0.6; Figure 4E). The DR_MOMP apoptosis score was lowest in PDX 
models in cluster C1 (mean = 152.9 nM) and, greatest in C3 (mean = 
246.0 nM; ANOVA p < 0.0001, Tukey post-hoc p ≤ 0.02; Figure 4F). There 
were no significant differences in DR_MOMP apoptosis scores when 
PDXs were grouped based on the CRIS subtypes (ANOVA p = 0.6; Figure 
4G).
APOPTO-CELL predicts apoptosis susceptibility of cells by modelling 
activation of executioner caspases and cleavage of their downstream 
substrates26. Exceeding a threshold of 25% substrate cleavage within 300 
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minutes served in previous studies as a surrogate for the competence of 
cells to undergo executioner (caspase 3) activation, in line with previous 
single-cell imaging findings 26, 31. APOPTO-CELL identified 24 PDX 
samples with less than 25% predicted substrate cleavage and 36 models 
with more than 25 % predicted substrate cleavage. However the predicted 
substrate cleavage did not correlate with responses of the PDX models to 
cetuximab (Fisher’s exact p = 0.89; Figure 4E). Further, there was no 
significant difference in the number of PDXs with substrate cleavage less 
or greater than 25% between protein clusters C1-C3 (Fisher’s exact p = 
0.09) or CRIS subtypes (Fisher’s exact p = 0.85; Figures 4FG).
We also questioned whether apoptosis signalling contributed to cetuximab 
responses only in specific protein clusters/molecular subtypes. There was 
no significant differences between DR_MOMP ‘stress dose’ scores and 
treatment responses when PDX models broken down into the three protein 
clusters C1, C2 and C3 (ANOVA interaction p = 0.9) or into the CRIS 
subtypes (ANOVA interaction p = 0.9). Similarly, there was no significant 
differences between the APOPTO-CELL class and treatment responses 
after stratifying for the protein cluster or CRIS (not-adjusted Fisher’s exact 
p > 0.12). Collectively, these data suggest that BCL2-dependent 
mitochondrial apoptosis and caspase-3 activation does not play a major 
role in cetuximab responses.
Next, we calculated the individual proliferative capacity of each PDX using 
an 11 gene signature index24, 25 using existing gene expression profiles13. 
Numerically, proliferation indices were lowest in protein cluster C3, and 
highest in C2. Statistical analysis revealed no significantly differences 
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between protein clusters (ANOVA p = 0.1; Figure 4H). CRIS-D had 
significant higher indices compared to the CRIS-B molecular subtype 
(Tukey post-hoc p = 0.02) and C (Tukey post-hoc p < 0.001; ANOVA p = 
0.001). Across all PDXs, the proliferation index gradually increased from 
PDXs with regressing toward progressing responses to cetuximab 
(ANOVA p-value of 0.01, Figure 4
J). Progressing PDX models had higher proliferation indices compared to 
stable (Tukey post-hoc p = 0.01 and 0.03) or regressing PDX models 
(Tukey post-hoc p = 0.001 and 0.02) if adjusted for either CRIS (ANOVA p 
= 0.01) or protein clusters (ANOVA p = 0.02). Collectively, these data 
suggested that proliferation rather than apoptosis score is a key 
determinant of cetuximab responses in ‘quadruple negative’ metastatic 
CRC PDX models. 
Development of an improved (phospho)protein response 
score
Because our previous protein analysis identified cell death markers (Figure 
2 and 3B; BAK, BCL2, cleaved Caspase-9, XIAP, etc.) that indicated 
responses to cetuximab, we finally decided to repeat the LASSO analysis 
with the 22 proteins, but replaced the apoptosis-related markers (BAK, 
BCL-2 (T56), cleaved Caspase-9 (D330) and XIAP) with the normalised 
DR_MOMP score. In addition, we removed the protein markers for AKT, 
mTOR, MAPK-ERK1/2 and PI3-Kinase p110α based on the assumption 
that these markers will likely not indicate the activation status of their 
respective signalling pathway. This enabled us to reduce the overall 
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number of proteins analysed. The LASSO analysis set only the coefficient 
of DR_MOMP to zero: PDK1 (S241; β = 6.3505), Caspase-8 (β = 5.2772), 
Shc (Y317; β = 4.2598), Stat3 (Y705; β = 2.6455), p27 (β = 0.6169), GSK-
3β (S9; β = 6.0001), HER3 (β = 3.5702) and PKC-alpha (S657; β = 
0.8191) were found with a positive coefficient. EGFR (Y1068; β = -1.065), 
Akt (S473; β = -5.5777), S6 Ribosomal Protein (S240/244; β = -4.3452), 
HER3 (Y1289; β = -5.4732), NF-kB-p65 (S536; β = -6.3106) and Gab-1 
(Y627; β = -4.6551) were found with a negative coefficients. The 
interception was 4.9424. The coefficients were in line with the first LASSO 
model (Spearman’s rank correlation rho = 0.88, p < 0.0001). Testing the 
updated regression model (14 markers) on PDX models showing no or 
only minor changes in tumour volume (n = 30), showed a significant 
improvement compared with the initial score, with 13 PDX models 
identified as true “progressing” (true positive), 10 as true “regressing” (true 
negative), 4 “regressing” as “progressing” and 3 ”progressing” as 
“regressing” models.
Discussion
The discovery of new prognostic biomarkers for cetuximab response is of 
crucial importance for improving efficiency, and efficacy, of the treatment 
of metastatic CRC. The genetic heterogeneity of metastatic CRC cancer 
makes it unlikely that one single protein will serve as a biomarker in all 
instances, and high throughput techniques such as RPPA may therefore 
be helpful in identifying predictive biomarker sets. Statistical analysis of 
our RPPA data showed significant correlation between levels of 20 
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(phospho)proteins with changes in tumour volume, as detected in PDX 
models. We identified markers indicating active signalling of the EGFR 
pathway such as EGFR (Y1068) itself and Akt (S473), Gab-1 (Y627), Shc 
(Y317), Stat3 (Y705) and PDK1 (S241) to significantly predict responses 
to cetuximab. Overall we found a high cross correlation between levels of 
these proteins markers across all samples, emphasising their potential to 
act as predictive biomarkers for cetuximab responses.
Interestingly, we found that high levels of phosphorylated EGFR at 
Tyr1068 and Akt at Ser473 indicated tumour progression, whereas 
regressing tumours showed a lack of phosphorylated Shc at Tyr317 and 
Stat3 at Tyr705. Phosphorylation of EGFR on Tyr1068 (and Tyr1086) 
leads to activation of the MAPK cascade and AKT activation32. Signal 
transducer and activator of transcription 3 (STAT3) and its phosphorylation 
are associated with cell growth and transformation33. The scaffolding 
protein Src homology and collagen domain protein (Shc) directs the EGF 
stimuli to pro-mitogenic, pro-survival and invasion signalling pathways in a 
time-dependent manner34. Phosphoinositide Dependent Protein Kinase 1 
(PDK1) is a crucial enzyme in transducing signals to multiple effector 
pathways including phosphoinositide 3-kinase (PI3K/AKT), Ras/mitogen-
activated protein kinase (MAPK), serum/glucocorticoid regulated kinase 
(SGK), p70 ribosomal protein S6 kinase (p70 S6 K) and members of 
protein kinase C (PKC) family. Phosphorylation of PDK1 on Ser241 is 
necessary for its activation35. Some of its substrates require a prior 
conformational switch to allow subsequent phosphorylation by PDK135 
rendering it as gatekeeper for those signalling pathways. We also found 
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that models expressing the human epidermal growth factor receptor 3 
(HER3, also EGFR3) were more likely to respond with tumour regression 
in response to cetuximab. In contrast, phosphorylation of HER3 on 
Tyr1289 was indicative for tumour progression. HER3 cannot be activated 
by ligand alone but its heterodimer with EGFR and HER2 is highly 
mitogenic36. Existing literature on the expression and relevance of HER3 is 
inconsistent, reporting association with either increased or decreased 
survival of CRC patients36. In advanced non-small cell lung cancer, 
abundant HER3 expression identifies gefitinib (EGFR inhibitor) sensitive 
cell lines37. In addition, Bosch-Vilaró et al.38 described a cetuximab-
induced feedback HER3 activation that reduces the response to 
cetuximab, and in pancreatic cancer, dimerization of EGFR and HER3 was 
reported to be necessary for downstream signalling39.
Further LASSO and binominal logistic regression analysis of these protein 
biomarkers delivered a refined protein signatures for predicting responses 
to cetuximab. Given that many of the identified markers in our signature 
are predicted to regulate cell proliferation, we also investigated a 
previously published, transcriptome-based proliferation score as to its 
predictive power24, 25. Using this score, we also found a significant 
correlation between cetuximab responses and the transcriptome-based 
proliferation score across all 63 PDX models investigated. Although the 
focus of our study was the delivery of a (phospo)protein signature, 
combining our protein score with the transcriptome-based proliferation 
score did not further increase the predictive power  of the protein 
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signature, suggesting that the signature was sufficient to describe the 
proliferation status of the PDX models in relation to cetuximab responses.
We also found that responses to cetuximab were dependent on protein 
clusters identified through unsupervised cluster analysis. One of the 
clusters, protein cluster 3 (C3), represented a cluster without progressing 
PDX models. C3 was characterised by PDK1-dependend active AKT 
signalling and inhibition of the cell cycle. The largest protein cluster (C1) in 
contrast showed mixed responses, and was characterised by genotoxic 
stress, inflammation and cell survival signalling. Cluster C2 was also 
composed of mixed responders and characterised by active EGFR 
signalling and inhibition of apoptosis. Compared to PDX models in C1 and 
C2, PDX models in C3 had lower levels of phosphorylated MEK1/2 
(S217/221). This suggests that cetuximab-resistant models in C1 and C2 
may potentially benefit from MEK inhibitors. We also explored the 
relationship between protein clusters and transcriptome-based molecular 
subtypes. CRIS molecular subtypes capture very well differences in 
intrinsic tumour cell gene expression13. CRIS-C was previously associated 
with sensitivity to cetuximab13, potentially a consequence of the lower 
representation of KRAS and NRAS mutations in this subtype13. We did not 
find that any of the three protein clusters showed a significant association 
with CRIS molecular subtypes. We also found that, when focusing on 
KRAS, NRAS, BRAF and PIK3CA wild type models, CRIS-C was not 
enriched in cetuximab responders (Figure 1D). Overall, this suggests that 
sensitivity to anti-EGFR therapy is predicted well by an analysis of 
(phospho)protein clusters.
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While we observed that increased proliferative capacity was associated 
with disease progression during cetuximab treatment (Figure 4J), 
competence to undergo mitochondrial apopotosis was not a major 
determinant of cetuximab responses. Both the DR_MOMP and APOPTO-
CELL apoptosis models have been shown to be prognostic for stage II and 
III CRC patients, but have not yet not been tested in the setting of 
metastatic CRC17, 31. 
Our data suggest that resistance to mitochondrial apoptosis is not critical 
for responses of metastatic CRC to cetuximab. While cetuximab was 
shown to induce apoptosis to a minor extent in colorectal cancer cells in 
previous studies40, combination therapy for example with regorafenib has 
been shown to be required for significant apoptosis induction by 
cetuximab41. In the setting of colorectal cancer, we have previously also 
shown that activation of Caspase-3 may be associated with a 
compensatory stimulation of cancer cell proliferation and adverse effects 
on clinical outcome42. Here, we also observed that PDX models with 
progressing tumours tended to have higher levels cleaved Caspase-3 
compared to models with stable or regressing tumours (Figure 2). It might 
be possible that activating apoptosis may have both beneficial and 
detrimental effects in the setting of metastatic CRC.
By comparing matched pre- and post-treatment samples, we also found 
that levels of GSK-3β (S9) were reduced in tissue after cetuximab 
treatment. The Glycogen synthase kinase 3β (GSK-3β) is a key player in 
the β-catenin/Wnt signalling pathway but also phosphorylates various 
transcription factors and structural, metabolic and signalling proteins43, 44. 
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Inhibition of GSK-3β activity by phosphorylation at Ser945 is a critical factor 
to allow many coupled signalling pathways to proceed43, 44. 96% of CRCs 
harbour increased oncogenic Wnt pathway alteration46 and dysregulation 
of GSK-3β signalling is associated with cancer and metabolic and 
degenerative disorders47. Inhibition of GSK-3β was reported to induce 
apoptosis and attenuated proliferation in colon cancer cells in vitro48 and in 
colon cancer xenografts49. It is possible that inhibition of GSK-3β would be 
desirable co-treatment with cetuxiumab. Lithium, which also acts as an 
inhibitor of GSK-3β50, was reported to supress cell proliferation in prostate 
cancer xenographs51 and may inhibit colon cancer metastatsis by blocking 
transforming growth factor-β-induced protein (TGFBIp) expression52 
downstream of GSK-353. Combining cetuximab with lithium or other GSK-
3 inhibitors may improve response to cetuximab.
In conclusion, we present here a 14 (phospho)protein marker signature 
that was predicting responses to cetuximab in mCRC tissue. Likewise, our 
findings emphasises GSK-3β to be potentially targetable for a co-
treatment with cetuximab.
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673 (A) Heatmap of protein levels determined by RPPA. PDX models were annotated 
674 with the, CRIS, the consensus protein cluster subtype, and response to cetuximab 
675 (top). Clustering was performed using Nonnegative Matrix Factorization (NMF) 
676 consensus clustering algorithm. The right annotations indicates proteins’ 
677 association to the protein clusters (Supplementary Figure 1). Chord diagrams show 
678 overlap between RPPA clusters and (B) response to cetuximab and (C) CRIS, and 
679 (D) overlap between CRIS and response to cetuximab.
680 Figure 2
681 Protein scores indicating proteins’ association to the PDX models’ response to 
682 cetuximab. Proteins’ scores for response to cetuximab after 3 week was calculated 
683 using PAM 27.
684 Figure 3
685 (A) Heatmap of Spearman’s rank correlation coefficients for proteins associated 
686 with differences in response to cetuximab from Figure 2. (B) Undirected graph of 
687 proteins found to be relevant in LASSO analysis. Intensity and colour of the edges 
688 indicate the correlation coefficient of (A). Grouping based on the signs of the 
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689 correlation coefficients and signs of the coefficients found by LASSO are indicated 
690 black & white nodes and plus & minus icons, respectively. (C) Protein found to be 
691 differential expressed in PDX models after treatment with cetuximab, based on 
692 pairwise comparison and Benjamin & Hochberg adjusted p-value. Dashed red lines 
693 indicate 0.05 significance threshold for p-value, and 2-fold or 1/2-fold protein level. 
694 The protein marker names and n-fold differences (treated to un-treated) in brackets 
695 were added for proteins passing all thresholds.
696 Figure 4
697 (A) Simplified illustration of the apoptotic signalling modelled in DR_MOMP and 
698 APOPTO-CELL. Absolute protein levels normalised to HeLa cells were measured 
699 using RPPA and used as input for (B) DR_MOMP and (C) APOPTO-CELL. 
700 Calculated DR MOMP values against (D) APOPTO-CELLs’ calculated substrate 
701 cleavage class with (E) differences in response to cetuximab, (F) RPPA protein 
702 cluster C3 and (G) CRIS. Calculated proliferation against (H) protein clusters, (I) 
703 CRIS and (J) response to cetuximab.
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(A) Heatmap of protein levels determined by RPPA. PDX models were annotated with the, CRIS, the 
consensus protein cluster subtype, and response to cetuximab (top). Clustering was performed using 
Nonnegative Matrix Factorization (NMF) consensus clustering algorithm. The right annotations indicates 
proteins’ association to the protein clusters (Supplementary Figure 1). Chord diagrams show overlap 
between RPPA clusters and (B) response to cetuximab and (C) CRIS, and (D) overlap between CRIS and 
response to cetuximab. 
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Protein scores indicating proteins’ association to the PDX models’ response to cetuximab. Proteins’ scores for 
response to cetuximab after 3 week was calculated using PAM[27]. 
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(A) Heatmap of Spearman’s rank correlation coefficients for proteins associated with differences in response 
to cetuximab from Figure 2. (B) Undirected graph of proteins found to be relevant in LASSO analysis. 
Intensity and colour of the edges indicate the correlation coefficient of (A). Grouping based on the signs of 
the correlation coefficients and signs of the coefficients found by LASSO are indicated black & white nodes 
and plus & minus icons, respectively. (C) Protein found to be differential expressed in PDX models after 
treatment with cetuximab, based on pairwise comparison and Benjamin & Hochberg adjusted p-value. 
Dashed red lines indicate 0.05 significance threshold for p-value, and 2-fold or 1/2-fold protein level. The 
protein marker names and n-fold differences (treated to un-treated) in brackets were added for proteins 
passing all thresholds. 
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(A) Simplified illustration of the apoptotic signalling modelled in DR_MOMP and APOPTO-CELL. Absolute 
protein levels normalised to HeLa cells were measured using RPPA and used as input for (B) DR_MOMP and 
(C) APOPTO-CELL. Calculated DR MOMP values against (D) APOPTO-CELLs’ calculated substrate cleavage 
class with (E) differences in response to cetuximab, (F) RPPA protein cluster C3 and (G) CRIS. Calculated 
proliferation against (H) protein clusters, (I) CRIS and (J) response to cetuximab. 
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